Skip to content
Business

M42, Zayed Authority and NMC Healthcare Sign Genetic Testing Pact for Mowj Children

The exploratory memorandum divides testing, counselling and oversight among the three partners but discloses no budget, number of children or start date.

·1 min read

Prefer Nakoda News on Google

M42, the Zayed Authority for People of Determination and NMC Healthcare signed a memorandum on genetic testing for children in Abu Dhabi.
M42, the Zayed Authority for People of Determination and NMC Healthcare signed a memorandum on genetic testing for children in Abu Dhabi.Photo: Emirates News Agency / Handout

M42 has signed a memorandum of understanding with the Zayed Authority for People of Determination and NMC Healthcare to explore genetic testing and research for children supported by the Mowj Early Intervention Centre, the Emirates News Agency reported on Monday.

The partners aim to improve understanding of neurodevelopmental disorders and developmental delays and to use the findings to guide more personalised clinical care and early intervention. The agreement is exploratory. No budget, number of children or timetable was disclosed.

The work is divided three ways. M42 will run the genetic testing, from sample collection and laboratory analysis to sharing results with partners under agreed governance and privacy frameworks. It will also take part in research into genetic factors linked to neurodevelopmental conditions. NMC Healthcare will handle informed consent, genetic counselling and the communication of results, and will support clinical care planning with specialist teams. The Zayed Authority will provide strategic oversight and beneficiary support and coordinate with relevant authorities so the initiative meets families' needs and regulatory requirements. The partners also plan to explore future precision medicine applications.

The pact builds on M42's earlier work with the authority through the Emirati Genome Programme for People of Determination and their families, extending the potential use of genomic insights to early intervention services within approved medical and regulatory frameworks. M42 describes itself as a global health leader powered by AI, technology and genomics.

"Harnessing genetic science to better understand neurodevelopmental disorders and developmental delays presents significant opportunities to advance medical knowledge, support clinical decision-making and inform appropriate interventions tailored to each child's needs," said Abdulla Abdulalee Al Humaidan, Acting Director-General of the Zayed Authority for People of Determination.

Dr David Kavanagh, General Manager of Omics at Integrated Health Solutions, M42, said the initiative would make advanced genomic science accessible to families seeking answers about their children's health conditions. Frank DeLisi, Senior Vice President of Operations at NMC Healthcare in Abu Dhabi, said the collaboration would let NMC advance clinical innovation, take part in genetic research and contribute to the development of precision medicine applications.

By

Nakoda News Gulf Desk

Business, technology and policy across the UAE, Saudi Arabia and the wider Gulf.

About the desk

Related coverage